Connect Biopharma Holdings Ltd is a biotechnology business based in the US. Connect Biopharma shares (CNTB) are listed on the NASDAQ and all prices are listed in US Dollars. Connect Biopharma employs 108 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.90 |
|---|---|
| 52-week range | $0.56 - $29.27 |
| 50-day moving average | $1.27 |
| 200-day moving average | $7.06 |
| Wall St. target price | $11.12 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.74 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9045 from 2022-07-01
| 1 week (2022-06-24) | 0.50% |
|---|---|
| 1 month (2022-06-02) | 14.48% |
| 3 months (2022-04-01) | -70.34% |
| 6 months (2021-12-31) | -82.44% |
| 1 year (2021-07-02) | -95.41% |
|---|---|
| 2 years (2020-06-28) | N/A |
| 3 years (2019-06-28) | N/A |
| 5 years (2017-06-28) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -26.72% |
| Return on equity TTM | -367.66% |
| Profit margin | 0% |
| Book value | $31.52 |
| Market capitalisation | $49.6 million |
TTM: trailing 12 months
We're not expecting Connect Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.